Form 4: HeartBeam Director Strome Boosts Equity Stake

HeartBeam Director and 10% owner Mark E. Strome reports new grants of restricted stock units and stock options, alongside significant existing beneficial ownership.

Summary

• Mark E. Strome, a Director and 10% owner of HeartBeam, Inc. (BEAT), has reported changes in his beneficial ownership.
• Strome indirectly holds 3,150,000 shares of Common Stock through Strome Mezzanine Fund II, LP, Mark E. Strome Living Trust, and Strome Dynasty, LLC.
• Strome directly holds 57,146 shares of Common Stock.
• A Restricted Stock Award (RSU) of 60,483 shares was granted on July 11, 2025, with a $0 price, vesting on the earlier of July 11, 2026, or the Issuer's 2026 annual meeting, subject to continued service as an Outside Director.
• Stock options to purchase 36,364 shares of Common Stock were granted on September 30, 2025, with an exercise price of $1.65 per share and an expiration date of September 30, 2035.
• These options vest in two tranches: one half on the three-month anniversary of the July 1, 2025 vesting commencement date, and the remaining half on the six-month anniversary of the vesting commencement date.
• The options were issued from the Company's 2022 Equity Incentive Plan.

Sentiment

Score: 7

Explanation: The reporting of new equity grants to a director and 10% owner, Mark E. Strome, indicates continued alignment of management and significant shareholders with the company's long-term performance, which is generally a positive signal.

Positives

• New equity grants to a Director and 10% owner, Mark E. Strome, align his interests with the long-term performance of HeartBeam, Inc.
• The significant existing beneficial ownership of 3,207,146 shares (direct and indirect) by a key insider demonstrates a substantial commitment to the company.

Future Outlook

The equity grants are structured to incentivize long-term commitment, with vesting periods extending into 2026 for RSUs and a 10-year expiration for options, suggesting an expectation of sustained value creation over these horizons.

Industry Context

Insider transactions, particularly by significant shareholders and directors, are closely watched in the medical technology and diagnostics sector as they can signal confidence in future product development, regulatory approvals, or market adoption, especially for early-stage companies like HeartBeam.

Related Party Transactions

• Mark E. Strome indirectly holds 3,150,000 shares through entities (Strome Mezzanine Fund II, LP, Mark E. Strome Living Trust, and Strome Dynasty, LLC) over which he has voting and dispositive authority, representing a related party beneficial ownership structure.

Stakeholder Impact

• Shareholders: Increased confidence due to strong insider alignment and commitment to the company's long-term success.
• Management/Employees: The equity grants serve as an incentive for the reporting person to contribute to the company's growth and share price appreciation.

Next Steps

• Vesting of 60,483 Restricted Stock Units on the earlier of July 11, 2026, or the 2026 annual meeting.
• Vesting of 36,364 stock options in two tranches: one half on the three-month anniversary of July 1, 2025, and the remaining half on the six-month anniversary of July 1, 2025.

Key Dates

Recommendation

The filing indicates a significant insider stake and new equity grants to a director and 10% owner, Mark E. Strome. This suggests strong alignment of interests between a key insider and the company's future performance, which is generally a positive signal for long-term investors. However, a Form 4 alone does not provide sufficient financial or operational data to warrant a 'buy' or 'sell' recommendation, thus a 'hold' is appropriate to observe further developments.

Keywords

HeartBeam, BEAT, Mark Strome, Insider Ownership, Form 4, Equity Grants, Restricted Stock Units, Stock Options, Director, 10% Owner